Bank Julius Baer & Co. Ltd Zurich Sells 523 Shares of Axon Enterprise, Inc $AXON

Bank Julius Baer & Co. Ltd Zurich lessened its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 8.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,974 shares of the biotechnology company’s stock after selling 523 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Axon Enterprise were worth $5,209,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Nuveen LLC acquired a new position in Axon Enterprise during the 1st quarter worth approximately $264,796,000. McElhenny Sheffield Capital Management LLC bought a new stake in shares of Axon Enterprise during the second quarter valued at approximately $255,833,000. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 3.5% during the second quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock valued at $7,399,515,000 after acquiring an additional 305,252 shares in the last quarter. Westfield Capital Management Co. LP raised its position in shares of Axon Enterprise by 29.8% during the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares during the period. Finally, Axiom Investors LLC DE acquired a new position in shares of Axon Enterprise during the first quarter worth approximately $93,088,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $521.99 on Friday. Axon Enterprise, Inc has a 52 week low of $469.24 and a 52 week high of $885.91. The company’s 50 day moving average price is $681.33 and its two-hundred day moving average price is $731.06. The stock has a market cap of $41.19 billion, a P/E ratio of 128.89, a P/E/G ratio of 29.49 and a beta of 1.45. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The business had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business’s revenue was up 30.6% compared to the same quarter last year. During the same period in the previous year, the business posted $1.45 earnings per share. On average, equities analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $591.04, for a total transaction of $5,910,400.00. Following the completion of the sale, the chief executive officer owned 3,023,982 shares in the company, valued at approximately $1,787,294,321.28. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Brittany Bagley sold 2,500 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $610.00, for a total transaction of $1,525,000.00. Following the completion of the transaction, the chief financial officer owned 91,092 shares in the company, valued at approximately $55,566,120. The trade was a 2.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 38,622 shares of company stock valued at $26,439,364. 4.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

AXON has been the subject of several research reports. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. JMP Securities reaffirmed a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a research note on Monday, September 29th. Needham & Company LLC reiterated a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a report on Wednesday, September 24th. Northland Securities set a $800.00 target price on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $814.00.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.